A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms

Trial Profile

A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Gandotinib (Primary)
  • Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia; Polycythaemia vera
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 10 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 04 Apr 2016 Planned End Date changed from 1 Apr 2016 to 1 Apr 2017, according to ClinicalTrials.gov record.
    • 02 Jun 2015 Planned End Date changed from 1 Mar 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top